Advertising suggests the oral anti-coagulant Eliquis offers significant advantages over warfarin in preventing stroke and bleeding. Actually the differences between the two drugs appear rather modest except in cost. The cash price of Eliquis is about $15 a day which translates to more than $5000 a year compared to a paltry $48 a year for warfarin. Additionally bleeding associated with warfarin can be rapidly reversed with vitamin K; bleeding from Eliquis has no antidote.